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Background: Combination chemotherapy yields better response rates which do not always lead to a
survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy
and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in
endometrial adenocarcinoma lead to significant advantage in favour of the combination.
Patients and methods: Eligible patients had histologically-proven advanced and/or recurrent endometrial
adenocarcinoma and were chemo-naïve. Treatment consisted of either DOX 60 mg/m2 alone or CDDP 50 mg/m2
added to DOX 60 mg/m2, every 4 weeks.
Results: A total of 177 patients were entered and median follow-up is 7.1 years. The combination
DOX–CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell
toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4
alopecia (72% versus 65%) and nausea/vomiting (36 % versus 12%). The combination DOX–CDDP provided
a significantly higher response rate than single agent DOX (P <0.001). Thirty-nine patients (43%) responded
on DOX–CDDP [13 complete responses (CRs) and 26 partial responses (PRs)], versus 15 patients (17%) on
DOX alone (8 CR and 7 PR). The median overall survival (OS) was 9 months in the DOX–CDDP arm versus
7 months in the DOX alone arm (Wilcoxon P = 0.0654). Regression analysis showed that WHO performance
status was statistically significant as a prognostic factor for survival, and stratifying for this factor, treatment
effect reaches significance (hazard ratio = 1.46, 95% confidence interval 1.05–2.03, P = 0.024).
Conclusions: In comparison to single agent DOX, the combination of DOX–CDDP results in higher but
acceptable toxicity. The response rate produced is significantly higher, and a modest survival benefit is
achieved with this combination regimen, especially in patients with a good performance status.
Key words: chemotherapy, cisplatin, doxorubicin, endometrial carcinoma, randomised clinical trial, phase III
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Introduction
Endometrial cancer remains one of the commonest gynaeco-
logical malignancies. Whilst many patients with early stage dis-
ease are cured by either surgery or radiotherapy, or a combination
of the two [1], 40% of patients are either not amenable to such
treatment due to metastatic disease, or subsequently relapse
following primary treatment. Such patients require systemic
therapy in the form of either hormonal or cytotoxic therapy [2–6].
Although the latter has been less extensively studied in endo-
metrial cancer, it is has been shown that response rates with
single-agent chemotherapy are comparable with those observed
following hormonal treatment, and response duration is generally
longer. Thus there is a need to define the optimal chemotherapy
regime. Whilst several phase II trials have identified chemothera-
peutic single agents with demonstrable objective response in
endometrial adenocarcinoma, of which doxorubicin (DOX) and
cisplatin (CDDP) seem to be the most active single agents [2–6],
the reported series are small and include patients with widely-
varying pre-treatment conditions, together with variable response
criteria.
As the combination of doxorubicin and cisplatin (DOX–CDDP)
has been shown to be of benefit in treating other gynaecological
malignancies [7], the current study, a multi-centre prospective
randomised trial, was designed to compare combination therapy
with DOX–CDDP versus DOX alone in endometrial carcinoma.
Patients and methods
Trial design
This protocol was designed as a randomised phase II/III study to determine
the antitumour activity of combination DOX–CDDP, versus single-agent
DOX, in patients with advanced primary endometrial cancer (i.e. beyond the
stage of local treatment), and in those with recurrent disease. The second
objective was to determine the toxicity of both treatment arms in comparable
patients.
Eligibility
Patients eligible for this study were those with histologically-proven
advanced and/or recurrent adenocarcinoma of the corpus uteri, all of whom
were first considered for radiotherapy and all of those with well differentiated
tumours for hormone therapy. Eligibility criteria were as follows: measurable
or evaluable lesions outside previously irradiated areas, with documented
progression; age ≤75 years; life expectancy ≥3 months; World Health Organ-
ization (WHO) performance status ≤2; and adequate bone marrow, renal and
liver function. All patients gave informed consent.
Excluded patients were those with the following: prior chemotherapy,
radiotherapy or hormone therapy within 4 weeks of trial entry; unresolved
toxic manifestations of their prior treatment; a concomitant or prior second
cancer, other than adequately-treated basal or squamous cell carcinoma of the
skin; brain or leptomeningeal involvement; pleural effusion, ascites, bone
lesions detectable only by bone scan or sclerotic bone metastases as the single
tumour response parameter; poor medical risk due to non-malignant disease,
such as active bacterial or other infection, heart failure or uncontrolled hyper-
tension; and expected difficulty with follow-up.
Baseline investigations included a medical history and physical gynaeco-
logical examination, assessment of performance status, laboratory profile,
urinalysis, electrocardiogram, clinical and/or radiological measurement of
indicator lesion(s), computed tomography (CT) scan or ultrasound.
Treatment and dose adjustments
Treatment consisted of DOX 60 mg/m2 and CDDP 50 mg/m2 or DOX 60 mg/m2
every 4 weeks. Cisplatin was only given after adequate diuresis had been
obtained with prehydration. Ancillary treatment was given as medically
indicated. Radiotherapy was allowed concomitantly for control of bone pain
or other reasons, provided that all evaluable lesions were not included in the
irradiated field.
The drug cycle was delayed by 1 week if toxicity persisted at the day of the
next cycle. If the treatment had to be delayed for two consecutive weeks, the
following dose adjustments were made: if the white blood cell (WBC) count
was 2.0–2.9 × 109/l or the platelet count 50–99 × 109/l, the DOX dose was
reduced to 50% and the CDDP dose remained at 100%; patients went off
study if the WBC was <2.0 × 109/l and/or the platelet count was <50 × 109/l
after 2 weeks delay. Doxorubicin dose adjustments according to haemato-
logical and hepatic toxicity were made as follows: according to nadir values
on day 15, adjustment to 50% was made if WBC was 1.0–1.9 × 109/l and/or
the platelet count was 50–74 × 109/l; to 25% if WBC was <1.0 × 109/l and/or
the platelet count was <50 × 109/l; to 50% if bilirubin was >25 µmol/l; and to
25% if bilirubin was >50 µmol/l. In cases of mucositis, the DOX dosage was
reduced to 50%. Dose adjustments of CDDP were made according to renal
and neurological toxicity: if the creatinine value rose above 125% of baseline
values, or the creatinine clearance decreased similarly, half the dose was
administered. Cisplatin was discontinued completely in patients developing
WHO grade II paresthesia and/or muscle weakness. Clinical evidence of
hearing loss was also a reason to discard CDDP. Antiemetics were used
according to local treatment protocol if gastrointestinal toxicity developed.
A total of at least two courses were given, unless this was not in the best
interest of the patient. The combination treatment was stopped on evidence of
disease progression after two courses, or of rapid progression (>50% increase
in volume or new lesions). If remission of the disease was achieved, treatment
was continued until either severe disease progression or severe toxicity
developed. DOX was discontinued after seven courses (cumulative dose of
420 mg/m2) regardless of the response. Complete responders in the combin-
ation arm then continued the treatment with CDDP alone for up to 4 months
from the moment of complete response. Treatment at disease progression was
not defined per protocol.
Toxicity and response evaluation
The overall assessment of response involved all parameters including
unidimensional (evaluable) and bidimensional measurable lesions, and non-
measurable manifestations. Lesions that could be measured by CT scan or
ultrasound were considered suitable for assessment of response provided that
they were measurable with one or two diameters, had a minimal diameter of
5 cm and were proven to be malignant disease. Evaluation was performed
after 8 weeks of treatment, or after at least two courses of treatment. Toxicity
was assessed according to WHO criteria. Patients were evaluable for toxicity
if they had received at least one cycle of treatment, and evaluable for overall
response after they had received at least two cycles of chemotherapy, with the
second and following treatment cycles not having been postponed for more
than 2 weeks. The duration of overall response was dated from commence-
ment of treatment until documentation of progression, and the duration of
complete response (CR) from the moment complete remission was first
recorded until documentation of progression. Survival will be dated from
commencement of treatment.
A CR was defined as disappearance of all known disease, determined by
two observations not less than 4 weeks apart. A partial response (PR) was
defined as a decrease of at least 50% in the sum of the product of the largest
perpendicular diameters of all measurable lesions, plus the sum of the
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diameter of all evaluable lesions, as determined by two observations not less
than 4 weeks apart, without progression or new lesions. There also had to be
an objective improvement in non-evaluable but clinically evident malignant
disease, and no increase of any manifestations of malignant disease. No
change was defined as a reduction of less than 50%, or an increase of less than
25%, in the size of one or more measurable lesions, without evidence of either
new lesions or an increase in any manifestation of malignant disease, until the
first evaluation date. Progression of disease was defined as an increase of
greater than 25% in the size of one or more measurable lesions, or the appear-
ance of a new lesion, and also by the occurrence of positive cytology of pleu-
ral effusion or ascitic fluid. Early progressive disease was defined as
progression that occurred after one cycle. Early tumour death was defined as
death occurring during the first 8 weeks due to tumour progression, whilst
toxic death was defined as death to which drug toxicity was thought to have
made a major contribution.
Statistical considerations
The trial was designed as a randomised phase II trial to be extended into a
comparative phase III trial in the case of sufficient responses. The phase II
part of the trial required a minimum of 20 patients in each arm, with five
patients to be added per each response observed during the first step. With
respect to the comparative phase III part of the trial, it was assumed that the
median duration of survival in the control (DOX) arm would be 8 months, and
the addition of CDDP would be justified if it could increase the median dura-
tion of survival to 1 year. A total of 192 deaths were required to detect such a
difference, with a two-sided type I error of 0.05 and a power of 80% [8]. During
randomisation, patients were stratified according to institution, degree of
differentiation (well versus moderate/poor), type of disease (locally advanced
versus recurrent) and performance status, using the minimisation technique
[9]. Survival curves were estimated using the Kaplan–Meier technique [10].
Duration of survival, time to progression (TTP) and progression-free survival
(PFS) were compared between both treatment arms using a two-sided log-
rank test [11]. Cox’s proportional hazards model was used, retrospectively
stratified for differentiation, type of disease and performance status [12].
Response rates were compared using chi-square tests; the percentages in the
tables are exact, whilst those in the text are rounded for clarity.
Results
Patient characteristics
From September 1988 to June 1994, 177 patients with advanced
inoperable or recurrent endometrial cancer were randomised by
35 institutions, with 90 patients in the DOX–CDDP combination
arm and 87 in the single-agent DOX arm. The study was stopped
early as recruitment decreased dramatically after the publication
of the Gynecologic Oncology Group results in 1993. Five
patients had no follow-up data (three, DOX–CDDP; two, DOX).
Twelve patients were found to be ineligible either due to inade-
quate disease stage (two, DOX–CDDP; two, DOX), absence of
measurable lesions (one, DOX–CDDP; three, DOX), the lesions
all being in a prior irradiated area (one, DOX–CDDP; one,
DOX), bad physical condition (one, DOX–CDDP) or prior treat-
ment (one, DOX).
Baseline characteristics of all patients are shown in Table 1;
these were similar in both treatment arms. Median age was
63 years (range 40–76) and 79% of all patients had a WHO per-
formance status of 0 or 1. International Federation of Gynecology
and Obstetrics (FIGO) stage at initial diagnosis was stage IV in
25% of patients. The tumour was well differentiated in 19% of
patients, and 59% had recurrent disease. Treatment received prior
to this protocol included surgery in 85% of patients, radiotherapy
in 50% (23% of patients had had a response), hormone therapy in
23% and chemotherapy in 1%.
Extent of exposure
A total of 790 cycles were given to all patients, with 480 to
patients in the DOX–CDDP arm, with a median of six cycles
(range 0–15), and 310 to patients in the DOX arm, with a median
of three cycles (range 0–7). DOX was given in 740 cycles: 430 in
the combination arm and 310 in the single-agent arm. DOX was
delayed in 25 cycles (6%) in the combination arm, and in 13 cycles
(4%) in the single-agent arm. DOX reductions were mainly made
in the combination arm (13% versus 5%). CDDP was given in
480 cycles, with a delay reported in 33 cycles (7%) and a dose
reduction in 12 cycles (3%). In a single instance, the DOX and
CDDP doses were both escalated in the combination arm, with no
escalation reported in the single-agent DOX arm.
Toxicity
Toxicity evaluation was based on the 165 patients (83 DOX–
CDDP and 82 DOX) who received at least one cycle. The com-
bination DOX–CDDP was more toxic than DOX alone. Haemato-
logical toxicities are presented in Table 2. The median WBC
nadir was 1.9 × 103/mm3 (range 0.2–17.7) in the DOX–CDDP
arm, and 2.6 × 103/mm3 (range 0.1–10.2) in the DOX arm. The
median platelet count nadir was 147 × 103/mm3 (range 11–720) in
the DOX–CDDP arm, and 232 × 103/mm3 (range 26–538) in the
DOX arm. WBC toxicity grade 3 and 4 was noted in 55% of
DOX–CDDP patients and in 30% of DOX patients. Antibiotics
were administered to nine patients: five in the combination arm
and four in the single-agent DOX arm. In 13% of DOX–CDDP
patients, thrombocytopenia grade 3 and 4 was reported. Grade 3
thrombocytopenia was reported in 5% of DOX patients; no grade
4 thrombocytopenia occurred in this arm. Six patients required a
blood transfusion, five of whom had received the combination
treatment. Haematological toxicity occurred mainly among the
radiotherapy pre-treated patients, being WBC grade 3 and 4 in
50%, versus 32%, and thrombocytopenia grade 3 and 4 in 11%,
versus 6%. This toxicity was not found to be cumulative by
increasing the number of cycles.
Analysis of the non-haematological toxicity is presented in
Table 3. The frequency of grade 3 or 4 non-haematological toxic-
ity in the combination arm compared with the single-agent arm
was alopecia (72% versus 65%), nausea/vomiting (36% versus
12%), oral (6% versus 0%), infection (2% versus 1%), cardiac
(1% versus 1%) and level of consciousness (0% versus 1%). Anti-
emetic therapy was used in 431 cycles (90%) of combination treat-
ment and in 226 (73%) of DOX alone. No diarrhoea of grade 3 or
4 was noted. Almost all grade 1 and 2 diarrhoea occurred in the
radiotherapy pre-treated patients, except for two patients in the
DOX arm. Only grade 1 and 2 neuropathies were reported, mainly
in the combination arm (25% versus 4%). Non-haematological
toxicities were also found not to be cumulative.
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Extensive toxicity was more often the reason for stopping
treatment in the DOX–CDDP arm than in the single-agent DOX
arm (10% versus 2%). One patient in the DOX–CDDP arm died
of toxicity 2 weeks after the start of the first cycle; the cause of
death being pneumonia, despite treatment with antibiotics.
Myelosuppression due to toxicity could not be excluded as
cause of death, despite the WBC count not being excessively low
(0.8 × 103/mm3). No fatal toxicities were reported in the DOX arm.
Efficacy evaluation
Efficacy analysis was performed on all randomised patients
(n = 177). Eight patients had no response assessed due to early
death (four, DOX–CDDP arm; four, DOX arm). Response to
treatment is summarised in Table 4. The combination of DOX–
CDDP provided a significantly higher response rate than the
single-agent DOX arm (P <0.001). Thirty-nine patients (43%)
responded to DOX–CDDP [95% confidence interval (CI) 33–54],
13 CRs and 26 PRs, versus 15 patients (17%) on DOX (95%
CI 3–15), 8 CRs and 7 PRs (Table 4). With respect to the type of
disease, 29% had advanced and 31% recurrent disease. As the
distribution of the type of disease among the responders was also
broadly equal in both arms, no correlation was seen between the
type of disease and the response rate. Prior radiotherapy and
hormonotherapy did not seem to influence the response rate in
Table 1. Baseline characteristics
CDDP, cisplatin; DOX, doxorubicin; FIGO, International Federation of Gynecology and Obstetrics; WHO, World 
Health Organization.
Treatment
DOX–CDDP DOX Total
No. of patients 90 87 177
Median age, years (range) 63 (40–76) 63 (41–76) 63 (40–76)
WHO performance status
0 29 39 68
1 42 29 71
2 15 17 32
Unknown 4 2 6
FIGO classification
I 37 24 61
II 15 17 32
III 13 17 30
IV 19 25 44
Unknown 6 4 10
Type of disease
Advanced primary 36 36 72
Recurrent 54 51 105
Tumour differentiation
Well 18 16 34
Moderately/poorly 72 71 143
Extent of disease at registration
Primary tumour 1 3 4
Locoregional recurrent 9 10 19
Metastatic disease 46 31 77
Primary not excised and metastatic 9 15 24
Locoregional recurrent and metastatic 21 25 46
Unknown 4 3 7
Prior treatment
Surgery 79 73 151
Radiotherapy 40 48 88
Chemotherapy 0 1 1
Hormonotherapy 25 15 40
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either arm, and there were no major differences in the response
rate of the various tumour sites between the treatment arms.
After a median follow-up of 86 months, 82 patients (91%)
treated with DOX–CDDP had died compared with 78 patients
(90%) treated with DOX. Of the patients in the combination arm,
73 had died because of malignant disease, one of toxicity, four of
cardiovascular disease, one of another chronic disease and three
for unknown reasons. In the single-agent treatment arm, 73 had
died because of malignant disease, three of cardiovascular disease
and two for other reasons.
The Kaplan–Meier curves, that illustrate overall survival (OS),
TTP and duration of response, are shown in Figures 1, 2 and 3.
Median OS was 9 months (95% CI 7–14) in the DOX–CDDP arm
versus 7 months (95% CI 4–9) in the DOX arm. The Kaplan–
Maier curve reveals no significant difference in survival
between the two treatment arms (log-rank, P = 0.107; Wilcoxon,
P = 0.064). Overall median TTP for all treated patients was
8 months (95% CI 7–11) in the DOX–CDDP arm and 7 months
(95% CI 6–10) in the DOX arm. The estimated median PFS was
8 months (95% CI 7–11) in the DOX–CDDP arm and 7 months
(95% CI 6–10) in the DOX arm. Median duration of response was
9 months in the DOX–CDDP arm versus 24 months in the DOX
arm (P = 0.008). Forty-three of 54 responders (34 of 39 in the
DOX–CDDP arm and 9 of 15 in the DOX arm) had progressed at
the cut-off date.
A Cox regression analysis was performed to identify prog-
nostic factors for survival. After taking account of age, WHO
performance status, FIGO stage, extent of disease and degree of
differentiation, only WHO performance status appeared to be
statistically significant. Stratifying only for this variable, the
treatment effect increased, reaching a significant difference in
favour of the combination arm (P = 0.024, hazard ratio = 1.46,
95% CI 1.05–2.03).
Discussion
Treatment of advanced or recurrent endometrial cancer with
prostagens yields an overall response rate of 30%, with a higher
response in patients with well differentiated tumours and in those
with long time intervals before relapse [3]. However, as hormone
receptors predict well for response to hormonal treatment, it is
imperative to find effective cytotoxic agents for the initial
management of those patients who are receptor negative.
Table 2. Haematological toxicity grade 3 and 4a
a165 evaluable patients.
DOX–CDDP, doxorubicin and cisplatin; DOX, doxorubicin; 
WBC, white blood cells.
Toxicity Treatment
DOX–CDDP, n (%) DOX, n (%)
WBC
Grade 3 37 (44.6) 14 (17.1)
Grade 4 9 (10.8) 11 (13.4)
Platelets
Grade 3 9 (10.8) 4 (4.9)
Grade 4 2 (2.4) 0 (0.0)
Table 3. Non-haematological toxicity during treatmenta
a165 evaluable patients.
DOX–CDDP, doxorubicin and cisplatin; DOX, doxorubicin; WHO, World Health Organization.
Toxic effect WHO grading
1 2 3 4
DOX–CDDP DOX DOX–CDDP DOX DOX–CDDP DOX DOX–CDDP DOX
Alopecia 1 5 14 15 59 50 1 3
Nausea/vomiting 9 28 34 29 29 10 1 0
Infection 7 4 6 1 0 1 2 0
Oral 18 16 7 7 5 0 0 0
Cardiac 5 1 1 0 1 1 0 0
Consciousness 4 0 0 1 0 1 0 0
Diarrhoea 15 3 7 4 0 0 0 0
Peripheral neuropathy 18 2 3 1 0 0 0 0
Drug fever 3 3 4 0 0 0 0 0
Pulmonary 4 0 0 1 0 0 0 0
Cutaneous 2 2 1 0 0 0 0 0
Local 6 1 0 0 0 0 0 0
Allergy 1 2 0 0 0 0 0 0
Other 14 7 6 3 1 1 0 0
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Since 1950, phase II trials have identified several chemothera-
peutic agents with a demonstrable objective response in endo-
metrial adenocarcinoma, including anthracycline, carboplatin,
CDDP, cyclophosphamide, 5-fluorouracil and hexamethylmela-
mine [5, 6, 13–15]. Experience with single-agent chemotherapy
has identified DOX and CDDP to be the most consistently active
agents investigated. Single-agent DOX was utilised in four trials
with overall response rates of 19–37%, as summarised in two
articles [5, 6]. Since 1975, single-agent CDDP has been used in
endometrial cancer, with reported response rates between 4% and
100% [5, 6, 14]. The large range in response rate of the different
trials can be explained by the difference in patient population. Most
trials including chemotherapy pre-treated and chemotherapy-
naïve patients showed a significant difference in response rate,
being worse in patients who received prior cytotoxic therapy.
Therefore, these results of previous studies suggest that CDDP is
only of use as a first-line agent in endometrial carcinoma, as in
breast cancer [16].
The combination of DOX–CDDP in endometrial cancer has
been evaluated in seven trials since 1984 [17–23]. Most of these
reports describe small trials without a control arm. In these trials,
response rates from 33% to 82% were reported in the 93 evalu-
ated patients. Seltzer et al. [18] showed in their trial that this drug
combination did not appear to be effective in the treatment of
recurrent endometrial cancer, although in contrast, our trial has not
shown any difference in response rate among primary advanced
Table 4. Response rate (intention-to-treat basis)
a177 evaluable patients.
CR, complete response; DOX, doxorubicin; DOX–CDDP, doxorubicin and cisplatin; PD, progressive disease; PR, 
partial response; SD, stable disease; WHO, World Health Organization.
WHO response Totala, n (%) DOX–CDDP, n (%) DOX, n (%)
CR 21 (11.9) 13 (14.4) 8 (9.2)
PR 33 (18.6) 26 (28.9) 7 (8.0)
SD 41 (23.2) 21 (23.3) 20 (23.0)
PD and early PD 45 (25.4) 13 (14.4) 32 (36.8)
Early death (malignant disease) 5 (2.8) 2 (2.2) 3 (3.4)
Early death (toxicity) 1 (0.6) 1 (1.1) 0 (0.0)
Early death (other cause) 2 (1.1) 1 (1.1) 1 (1.1)
Insufficient data 27 (15.3) 12 (13.3) 15 (17.2)
Unknown 2 (1.1) 1 (1.1) 1 (1.1)
Figure 1. Kaplan–Maier plot of overall survival according to treatment arm.
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and recurrent disease. In a trial of the Gynecologic Oncology
Group, Thigpen et al. [22] used single-agent DOX as a control
arm, whilst Long et al. [23] compared the use of methotrexate,
vinblastine, DOX and CDDP to DOX–CDDP, the latter showing
a response rate of 26% with the combination of DOX–CDDP in
only 15 patients. Thigpen et al. [22] showed a response rate of
45% with combination treatment and a 27% response rate in the
single-agent arm among 223 evaluable patients, although there
was no overall survival benefit of the combination treatment in
his cohort.
An initial analysis performed on 113 evaluable patients from
our trial showed a difference in the duration of survival between
both treatment arms in favour of the combination arm (12.4
versus 7.6 months) [24]. However, the final analysis has shown a
Figure 2. Kaplan–Maier plot of time to progression according to treatment arm.
Figure 3. Kaplan–Maier plot of duration of response according to treatment arm.
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smaller difference, with some evidence of an early separation
followed by a convergence in the survival curve. There is also
evidence that the duration of response may be longer on the DOX
arm for the few responding patients, as shown in Figure 3. This
long duration of remission may be due to chance alone, or to the
possible influence of prior hormonal therapy (some patients
could have had a non-documented oestrogen withdrawal) or
demonstrate a subgroup of patients with highly DOX-sensitive
tumours. Although the median number of cycles in the DOX–
CDDP arm was higher than in the DOX arm, explained by the
fact that CDDP alone was continued in responding patients in
the combination arm, no major differences were noted between
the treatment arms in the response of the various tumour sites,
and therefore the addition of CDDP does not seem to influence
the response of specific sites.
Combination treatment was more toxic than DOX alone, with
observed toxicity being mainly primarily haematological and
gastrointestinal. However, in general, this was acceptable, and
similar to that observed in earlier trials.
Thus, overall, our randomised controlled trial shows that in
comparison to single-agent DOX, the combination of DOX–
CDDP results in higher toxicity, but also a significantly higher
response rate, and overall provides a moderate benefit in survival
in patients with a good performance status.
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